Myo Htut MD

Hematologic Oncology

Physician

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-408-3911

Dr. Htut is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Htut's full profile Already have an account?

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2009
MedStar Health Georgetown University/Harbor HospitalResidency, Internal Medicine, 1999 - 2002
University Institute of Medicine 1Class of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2002 - 2027
CO State Medical License 2008 - 2011
MI State Medical License 2002 - 2009
PA State Medical License 2004 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
TERMINATED
PHASE2
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
COMPLETED
PHASE1
CT Antigen TCR-Engineered T Cells for Myeloma Start of enrollment: 2013 Oct 15
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies.
Tamer Othman, John H Baird, Yan Wang, Stacy Pak, Hannah Zhong
Transplantation and Cellular Therapy. 2026-08-01
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.
Susan Bal, Myo Htut, Omar Nadeem, Larry D Anderson Jr, Tara Gregory
Blood. 2026-06-02
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.
Carlyn Rose Tan, Saad Usmani, Andriy Derkach, Andre de Meneze Silva Corraes, Ricardo Parrondo
Blood Advances. 2026-05-12

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Myo Htut, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD84: A Potential Novel Therapeutic Target in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH MeetingDecember 2nd, 2016